RTP801/REDD1: A stress coping regulator that turns into a troublemaker in neurodegenerative disorders

Frontiers in Cellular Neuroscience

Volumn 8, Issue OCT, 2014, Pages

  Canal, Mercè ^a   Romaní Aumedes, Joan ^a   Martín Flores, Núria ^a   Pérez Fernández, Víctor ^a   Malagelada, Cristina ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Akt; mTOR; Neurodegeneration; Neuron; Parkinson s disease; REDD1; RTP801; Stress

Indexed keywords

AMYLOID BETA PROTEIN; CCAAT ENHANCER BINDING PROTEIN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; HYPOXIA INDUCIBLE FACTOR 1; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN KINASE R; PROTEIN P53; REDD1 PROTEIN; REGULATOR PROTEIN; RTP801 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ELK 1; TRANSCRIPTION FACTOR SP1; TUBERIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL STRESS; CELL VIABILITY; CELLULAR DISTRIBUTION; CLINICAL TRIAL (TOPIC); COPING BEHAVIOR; DNA DAMAGE; DOWN REGULATION; GENE EXPRESSION; HUMAN; INTRACELLULAR SIGNALING; MICROARRAY ANALYSIS; NERVE CELL; NERVE CELL NECROSIS; NERVE DEGENERATION; NERVE FUNCTION; NONHUMAN; PARKINSON DISEASE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS INHIBITION; REGULATORY MECHANISM; SUBSTANTIA NIGRA PARS COMPACTA; TRANSCRIPTION REGULATION; TRANSLATION REGULATION; TUBEROUS SCLEROSIS; UPREGULATION;

EID: 84908267031     PISSN: 16625102     EISSN: None     Source Type: Journal    
DOI: 10.3389/fncel.2014.00313     Document Type: Article

References (73)

1. Baltazar, M. T., Dinis-Oliveira, R. J., de Lourdes Bastos, M., Tsatsakis, A. M., Duarte, J. A., and Carvalho, F. (2014). Pesticides exposure as etiological factors of Parkinson’s disease and other neurodegenerative diseases-A mechanistic approach. Toxicol. Lett. 230, 85–103. doi: 10.1016/j.toxlet.2014.01.039
2. Bao, X. Q., Kong, X. C., Kong, L. B., Wu, L. Y., Sun, H., and Zhang, D. (2014). Squamosamide derivative FLZ protected dopaminergic neuronby activating Akt signaling pathway in 6-OHDA-induced in vivo and in vitro Parkinson’s disease models. Brain Res. 1547, 49–57. doi: 10.1016/j.brainres.2013.12.026
3. Bao, X. Q., Kong, X. C., Qian, C., and Zhang, D. (2012). FLZ protects dopaminergic neuron through activating protein kinase B/mammalian target of rapamycin pathway and inhibiting RTP801 expression in Parkinson’s disease models. Neuroscience 202, 396–404. doi: 10.1016/j.neuroscience.2011.11.036
4. Brafman, A., Mett, I., Shafir, M., Gottlieb, H., Damari, G., Gozlan-Kelner, S., et al. (2004). Inhibition of oxygen-induced retinopathy in RTP801-deficient mice. Invest. Ophthalmol. Vis. Sci. 45, 3796–3805. doi: 10.1167/iovs.04-0052
5. Brugarolas, J., Lei, K., Hurley, R. L., Manning, B. D., Reiling, J. H., Hafen, E., et al. (2004). Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev. 18, 2893–2904. doi: 10.1101/gad.1256804
6. Cai, S. L., Tee, A. R., Short, J. D., Bergeron, J. M., Kim, J., Shen, J., et al. (2006). Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning. J. Cell. Biol. 173, 279–289. doi: 10.1083/jcb.200507119
7. Cammalleri, M., Lütjens, R., Berton, F., King, A. R., Simpson, C., Francesconi, W., et al. (2003). Time-restricted role for dendritic activation of the mTOR-p70S6K pathway in the induction of late-phase long-term potentiation in the CA1. Proc. Natl. Acad. Sci. U S A 100, 14368–14373. doi: 10.1073/pnas.2336098100
8. Cannon, J. R., and Greenamyre, J.T. (2011). The role of environmental exposures in neurodegeneration and neurodegenerative diseases. Toxicol. Sci. 124, 225–250. doi: 10.1093/toxsci/kfr239
9. Cheng, S. Y., Oh, S., Velasco, M., Ta, C., Montalvo, J., and Calderone, A. (2014). RTP801 regulates maneb- and mancozeb-induced cytotoxicity via NF-kappaB. J. Biochem. Mol. Toxicol. 28, 302–311. doi: 10.1002/jbt.21566
10. Corradetti, M. N., Inoki, K., and Guan, K. L. (2005). The stress-inducted proteins RTP801 and RTP801L are negative regulators of the mammalian target of rapamycin pathway. J. Biol. Chem. 280, 9769–9772. doi: 10.1074/jbc.c400557200
11. Damjanac, M., Page, G., Ragot, S., Laborie, G., Gil, R., Hugon, J., et al. (2009). PKR, a cognitive decline biomarker, can regulate translation via two consecutive molecular targets p53 and Redd1 in lymphocytes of AD patients. J. Cell. Mol. Med. 13, 1823–1832. doi: 10.1111/j.1582-4934.2009.00688.x
12. Dauer, W., and Przedborski, S. (2003). Parkinson’s disease: mechanisms and models. Neuron 39, 889–909. doi: 10.1016/S0896-6273(03)00568-3
13. Dehay, B., Bové, J., Rodríguez-Muela, N., Perier, C., Recasens, A., Boya, P., et al. (2010). Pathogenic lysosomal depletion in Parkinson’s disease. J. Neurosci. 30, 12535–12544. doi: 10.1523/jneurosci.1920-10.2010
14. del Olmo-Aguado, S., Núñez-Árez, C., Ji, D., Manso, A. G., and Osborne, N. N. (2013). RTP801 immunoreactivity in retinal ganglion cells and its down-regulation in cultured cells protect them from light and cobalt chloride. Brain Res. Bull. 98, 132–144. doi: 10.1016/j.brainresbull.2013.08.002
15. DeYoung, M. P., Horak, P., Sofer, A., Sgroi, D., and Ellisen, L. W. (2008). Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev. 22, 239–251. doi: 10.1101/gad.1617608
16. Ellisen, L. W., Ramsayer, K. D., Johannessen, C. M., Yang, A., Beppu, H., Minda, K., et al. (2002). REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species. Mol. Cell 10, 995–1005. doi: 10.1016/s1097-2765(02)00706-2
17. Favier, F. B., Costes, F., Defour, A., Bonnefoy, R., Lefai, E., Baugé, S., et al. (2010). Downregulation of Akt/mammalian target of rapamycin pathway in skeletal muscle is associated with increased REDD1 expression in response to chronic hypoxia. Am. J. Physiol. Regul. Integr. Comp. Physiol. 298, R1659–R1666. doi: 10.1152/ajpregu.00550.2009
18. Fulda, S., Gorman, A. M., Hori, O., and Samali, A. (2010). Cellular stress responses: cell survival and cell death. Int. J. Cell Biol. 2010:214074. doi: 10.1155/2010/214074
19. Greene, L. A., Levy, O., and Malagelada, C. (2011). Akt as a victim, villain and potential hero in Parkinson’s disease pathophysiology and treatment. Cell. Mol. Neurobiol. 31, 969–978. doi: 10.1007/s10571-011-9671-8
20. Hernández, G., Lal, H., Fidalgo, M., Guerrero, A., Zalvide, J., Force, T., et al. (2011). A novel cardioprotective p38-MAPK/mTOR pathway. Exp. Cell Res. 317, 2938–2949. doi: 10.1016/j.yexcr.2011.09.011
21. Hobbs, R. M., Seandel, M., Falciatori, I., Rafii, S., and Pandolfi, P. P. (2010). Plzf regulates germline progenitor self-renewal by opposing mTORC1. Cell 142, 468–479. doi: 10.1016/j.cell.2010.06.041
22. Hoeffer, C. A., and Klann, E. (2010). mTOR signaling: at the crossroads of plasticity, memory and disease. Trends Neurosci. 33, 67–75. doi: 10.1016/j.tins.2009.11.003
23. Horak, P., Crawford, A. R., Vadysirisack, D. D., Nash, Z. M., DeYoung, M. P., Sgroi, D., et al. (2010). Negative feedback control of HIF-1 through REDD1-regulated ROS suppresses tumorigenesis. Proc. Natl. Acad. Sci. U S A 107, 4675–4680. doi: 10.1073/pnas.0907705107
24. Hwang-Verslues, W. W., Chang, P. H., Wei, P. C., Yang, C. Y., Huang, C. K., Kuo, W. H., et al. (2011). miR-495 is upregulated by E12/E47 in breast cancer stem cells and promotes oncogenesis and hypoxia resistance via downregula-tion of E-cadherin and REDD1. Oncogene 30, 2463–2474. doi: 10.1038/onc.2010.618
25. Inoki, K., Li, Y., Xu, T., and Guan, K. L. (2003). Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 17, 1829–1834. doi: 10.1101/gad.1110003
26. Inoki, K., Li, Y., Zhu, T., Wu, J., and Guan, K. L. (2002). TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 4, 648–657. doi: 10.1038/ncb839
27. Jana, N. R., Zemskov, E. A., Wang, G., and Nukina, N. (2001). Altered protea-somal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mito-chondrial cytochrome c release. Hum. Mol. Genet. 10, 1049–1059. doi: 10.1093/hmg/10.10.1049
28. Jin, H. O., An, S., Lee, H. C., Woo, S. H., Seo, S. K., Choe, T. B., et al. (2007). Hypoxic condition- and high cell density-induced expression of Redd1 is regulated by activation of hypoxia-inducible factor-1alpha and Sp1 through the phosphatidylinositol 3-kinase/Akt signaling pathway. Cell. Signal. 19, 1393–1403. doi: 10.1016/j.cellsig.2006.12.014
29. Jin, H. O., Seo, S. K., Woo, S. H., Kim, E. S., Lee, H. C., Yoo, D. H., et al. (2009). Activating transcription factor 4 and CCAAT/enhancer-binding protein-beta negatively regulate the mammalian target of rapamycin via Redd1 expression in response to oxidative and endoplasmic reticulum stress. Free Radic. Biol. Med. 46, 1158–1167. doi: 10.1016/j.freeradbiomed.2009.01.015
30. Katiyar, S., Liu, E., Knutzen, C. A., Lang, E. S., Lombardo, C. R., Sankar, S., et al. (2009). REDD1, an inhibitor of mTOR signalling, is regulated by the CUL4A-DDB1 ubiquitin ligase. EMBO Rep. 10, 866–872. doi: 10.1038/embor.2009.93
31. Keller, J. N., Hanni, K. B., and Markesbery, W. R. (2000). Impaired proteasome function in Alzheimer’s disease. J. Neurochem. 75, 436–439. doi: 10.1046/j.1471-4159.2000.0750436.x
32. Kim, J. R., Lee, S. R., Chung, H. J., Kim, S., Baek, S. H., Kim, J. H., et al. (2003). Identification of amyloid beta-peptide responsive genes by cDNA microarray technology: involvement of RTP801 in amyloid beta-peptide toxicity. Exp. Mol. Med. 35, 403–411. doi: 10.1038/emm.2003.53
33. Kimball, S. R., Do, A. N., Kutzler, L., Cavener, D. R., and Jefferson, L. S. (2008). Rapid turnover of the mTOR complex 1 (mTORC1) repressor REDD1 and activation of mTORC1 signaling following inhibition of protein synthesis. J. Biol. Chem. 283, 3465–3475. doi: 10.1074/jbc.m706643200
34. Laplante, M., and Sabatini, D. M. (2012). mTOR signaling in growth control and disease. Cell 149, 274–293. doi: 10.1016/j.cell.2012.03.017
35. Lee, D. U., Huang, W., Rittenhouse, K. D., and Jessen, B. (2012). Retina expression and cross-species validation of gene silencing by PF-655, a small interfering RNA against RTP801 for the treatment of ocular disease. J. Ocul. Pharmacol. Ther. 28, 222–230. doi: 10.1089/jop.2011.0116
36. Levy, O. A., Malagelada, C., and Greene, L. A. (2009). Cell death pathways in Parkinson’s disease: proximal triggers, distal effectors and final steps. Apoptosis 14, 478–500. doi: 10.1007/s10495-008-0309-3
37. Li, X. H., Ha, C. T., Fu, D., and Xiao, M. (2012). Micro-RNA30c negatively regulates REDD1 expression in human hematopoietic and osteoblast cells after gamma-irradiation. PLoS One 7:e48700. doi: 10.1371/journal.pone.0048700
38. Lin, L., Qian, Y., Shi, X., and Chen, Y. (2005a). Induction of a cell stress response gene RTP801 by DNA damaging agent methyl methanesulfonate through CCAAT/enhancer binding protein. Biochemistry 44, 3909–3914. doi: 10.1021/bi047574r
39. Lin, L., Stringfield, T. M., Shi, X., and Chen, Y. (2005b). Arsenite induces a cell stress-response gene, RTP801, through reactive oxygen species and transcription factors Elk-1 and CCAAT/enhancer-binding protein. Biochem. J. 392(Pt. 1), 93–102. doi: 10.1042/bj20050553
40. Ma, X. M., and Blenis, J. (2009). Molecular mechanisms of mTOR-mediated translational control. Nat. Rev. Mol. Cell Biol. 10, 307–318. doi: 10.1038/nrm2672
41. Malagelada, C., Jin, Z. H., and Greene, L. A. (2008). RTP801 is induced in Parkinson’s disease and mediates neuron death by inhibiting Akt phosphory-lation/activation. J. Neurosci. 28, 14363–14371. doi: 10.1523/jneurosci.3928-08.2008
42. Malagelada, C., Jin, Z. H., Jackson-Lewis, V., Przedborski, S., and Greene, L. A. (2010). Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson’s disease. J. Neurosci. 30, 1166–1175. doi: 10.1523/jneurosci.3944-09.2010
43. Malagelada, C., López-Toledano, M. A., Willett, R. T., Jin, Z. H., Shelanski, M. L., and Greene, L. A. (2011). RTP801/REDD1 regulates the timing of cortical neurogenesis and neuron migration. J. Neurosci. 31, 3186–3196. doi: 10.1523/jneurosci.4011-10.2011
44. Malagelada, C., Ryu, E. J., Biswas, S. C., Jackson-Lewis, V., and Greene, L. A. (2006). RTP801 is elevated in Parkinson brain substantia nigral neurons and mediates death in cellular models of Parkinson’s disease by a mechanism involving mammalian target of rapamycin inactivation. J. Neurosci. 26, 9996–10005. doi: 10.1523/jneurosci.3292-06.2006
45. McNaught, K. S., Belizaire, R., Isacson, O., Jenner, P., and Olanow, C. W. (2003). Altered proteasomal function in sporadic Parkinson’s disease. Exp. Neurol. 179, 38–46. doi: 10.1006/exnr.2002.8050
46. Michel, G., Matthes, H. W., Hachet-Haas, M., El Baghdadi, K., de Mey, J., Pepperkok, R., et al. (2014). Plasma membrane translocation of REDD1 governed by GPCRs contributes to mTORC1 activation. J. Cell Sci. 127(Pt. 4), 773–787. doi: 10.1242/jcs.136432
47. Migliore, L., and Coppede, F. (2009). Genetics, environmental factors and the emerging role of epigenetics in neurodegenerative diseases. Mutat. Res. 667, 82–97. doi: 10.1016/j.mrfmmm.2008.10.011
48. Nguyen, Q. D., Schachar, R. A., Nduaka, C. I., Sperling, M., Basile, A. S., Klamerus, K. J., et al. (2012a). Dose-ranging evaluation of intravitreal siRNA PF-04523655 for diabetic macular edema (the DEGAS study). Invest. Ophthalmol. Vis. Sci. 53, 7666–7674. doi: 10.1167/iovs.12-9961
49. Nguyen, Q. D., Schachar, R. A., Nduaka, C. I., Sperling, M., Basile, A. S., Klamerus, K. J., et al. (2012b). Phase 1 dose-escalation study of a siRNA targeting the RTP801 gene in age-related macular degeneration patients. Eye (Lond) 26, 1099–1105. doi: 10.1038/eye.2012.106
50. Ota, K. T., Liu, R. J., Voleti, B., Maldonado-Aviles, J. G., Duric, V., Iwata, M., et al. (2014). REDD1 is essential for stress-induced synaptic loss and depressive behavior. Nat. Med. 20, 531–535. doi: 10.1038/nm.3513
51. Pieri, B. L., Souza, D. R., Luciano, T. F., Marques, S. O., Pauli, J. R., Silva, A. S., et al. (2014). Effects of physical exercise on the P38MAPK/REDD1/14-3-3 pathways in the Myocardium of Diet-Induced obesityrats. Horm. Metab. Res. 46, 621–627. doi: 10.1055/s-0034-1371824
52. Pineau, P., Volinia, S., McJunkin, K., Marchio, A., Battiston, C., Terris, B., et al. (2010). miR-221 overexpression contributes to liver tumorigenesis. Proc. Natl. Acad. Sci. U S A 107, 264–269. doi: 10.1073/pnas.0907904107
53. Qian, Y., Castranova, V., and Shi, X. (2003). New perspectives in arsenic-induced cell signal transduction. J. Inorg. Biochem. 96, 271–278. doi: 10.1016/s0162-0134(03)00235-6
54. Reiling, J. H., and Hafen, E. (2004). The hypoxia-induced paralogs Scylla and Charybdis inhibit growth by down-regulating S6K activity upstream of TSC in Drosophila. Genes Dev. 18, 2879–2892. doi: 10.1101/gad.322704
55. Rittenhouse, K. D., Johnson, T. R., Vicini, P., Hirakawa, B., Kalabat, D., Yang, A. H., et al. (2014). RTP801 gene expression is differentially upregulated in retinopathy and is silenced by PF-04523655, a 19-Mer siRNA directed against RTP801. Invest. Ophthalmol. Vis. Sci. 55, 1232–1240. doi: 10.1167/iovs.13-13449
56. Romaní-Aumedes, J., Canal, M., Martín-Flores, N., Sun, X., Pérez-Fernández, V., Wewering, S., et al. (2014). Parkin loss of function contributes to RTP801 elevation and neurodegeneration in Parkinson’s disease. Cell Death Dis. 5:e1364. doi: 10.1038/cddis.2014.333
57. Ryu, E. J., Angelastro, J. M., and Greene, L. A. (2005). Analysis of gene expression changes in a cellular model of Parkinson disease. Neurobiol. Dis. 18, 54–74. doi: 10.1016/j.nbd.2004.08.016
58. Shoshani, T., Faerman, A., Mett, I., Zelin, E., Tenne, T., Gorodin, S., et al. (2002). Identification of a novel hypoxia-inducible factor 1-responsive gene, RTP801, involved in apoptosis. Mol. Cell. Biol. 22, 2283–2293. doi: 10.1128/mcb.22.7.2283-2293.2002
59. Sofer, A., Lei, K., Johannessen, C. M., and Ellisen, L. W. (2005). Regulation of mTOR and cell growth in response to energy stress by REDD1. Mol. Cell. Biol. 25, 5834–5845. doi: 10.1128/mcb.25.14.5834-5845.2005
60. Sun, X., Liu, J., Crary, J. F., Malagelada, C., Sulzer, D., Greene, L. A., et al. (2013). ATF4 protects against neuronal death in cellular PD models by maintaining levels of parkin. J. Neurosci. 33, 2398–2407. doi: 10.1523/jneurosci.2292-12.2013
61. Tain, L. S., Mortiboys, H., Tao, R. N., Ziviani, E., Bandmann, O., and Whit-worth, A. J. (2009). Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss. Nat. Neurosci. 12, 1129–1135. doi: 10.1038/nn.2372
62. Tan, C. Y., and Hagen, T. (2013). mTORC1 dependent regulation of REDD1 protein stability. PLoS One 8:e63970. doi: 10.1371/journal.pone.0063970
63. Tanaka, K., and Matsuda, N. (2014). Proteostasis and neurodegeneration: the roles of proteasomal degradation and autophagy. Biochim. Biophys. Acta 1843, 197–204. doi: 10.1016/j.bbamcr.2013.03.012
64. Tang, S. J., Reis, G., Kang, H., Gingras, A. C., Sonenberg, N., and Schuman, E. M. (2002). A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus. Proc. Natl. Acad. Sci. U S A 99, 467–472. doi: 10.1073/pnas.012605299
65. Tarazi, F. I., Sahli, Z. T., Wolny, M., and Mousa, S. A. (2014). Emerging therapies for Parkinson’s disease: from bench to bedside. Pharmacol. Ther. doi: 10.1016/j. pharmthera.2014.05.010. [Epub ahead of print].
66. Tee, A. R., Manning, B. D., Roux, P. P., Cantley, L. C., and Blenis, J. (2003). Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr. Biol. 13, 1259–1268. doi: 10.1016/s0960-9822(03)00506-2
67. Vega-Rubin-de-Celis, S., Abdallah, Z., Kinch, L., Grishin, N. V., Brugarolas, J., and Zhang, X. (2010). Structural analysis and functional implications of the negative mTORC1 regulator REDD1. Biochemistry 49, 2491–2501. doi: 10.1021/bi902135e
68. Wang, Z., Malone, M. H., Thomenius, M.J., Zhong, F., Xu, F., and Distelhorst, C. W. (2003). Dexamethasone-induced gene 2 (dig2)isa novel pro-survival stress gene induced rapidly by diverse apoptotic signals. J. Biol. Chem. 278, 27053–27058. doi: 10.1074/jbc.m303723200
69. Whitney, M. L., Jefferson, L. S., and Kimball, S. R. (2009). ATF4 is necessary and sufficient for ER stress-induced upregulation of REDD1 expression. Biochem. Biophys. Res. Commun. 379, 451–455. doi: 10.1016/j.bbrc.2008.12.079
70. Wu, X. M., Qian, Z. M., Zhu, L., Du, F., Yung, W. H., Gong, Q., et al. (2011). Neuroprotective effect of ligustilide against ischaemia-reperfusion injury via up-regulation of erythropoietin and down-regulation of RTP801. Br. J. Pharmacol. 164, 332–343. doi: 10.1111/j.1476-5381.2011.01337.x
71. Zhang, D., Zhang, J. J., and Liu, G. T. (2007a). The novel squamosamide derivative FLZ protects against 6-hydroxydopamine-induced apoptosis through inhibition of related signal transduction in SH-SY5Y cells. Eur. J. Pharmacol. 561, 1–6. doi: 10.1016/j.ejphar.2006.11.015
72. Zhang, D., Zhang, J. J., and Liu, G. T. (2007b). The novel squamosamide derivative (compound FLZ) attenuated 1-methyl, 4-phenyl-pyridinium ion (MPP+)-induced apoptosis and alternations of related signal transduction in SH-SY5Y cells. Neuropharmacology 52, 423–429. doi: 10.1016/j.neuropharm.2006.08.020
73. Zhou, Y., Wang, Q., Guo, Z., Weiss, H. L., and Evers, B. M. (2012). Nuclear factor of activated T-cell c3 inhibition of mammalian target of rapamycin signaling through induction of regulated in development and DNA damage response 1 in human intestinal cells. Mol. Biol. Cell 23, 2963–2972. doi: 10.1091/mbc.e12-01-0037